Mechanistic studies have implicated the alternative complement pathway, specifically C5a receptor activation, in the pathogenesis of anti-neutrophil cytoplasmic antibody-associated vasculitis. Results from a phase 2 trial suggest that C5a receptor blockade could enable the reduced use or complete withdrawal of steroids from induction protocols.
Refers to Jayne, D. R. et al. Randomized trial of C5a teceptor inhibitor avacopan in ANCA-asociated vasculitis. J. Am. Soc. Nephrol.http://dx.doi.org/10.1681/ASN.2016111179 (2017)